PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
January 19, 2017 6:30 AM ET ANNAPOLIS, Md. and GAITHERSBURG, Md., Jan. 19, 2017 /PRNewswire/ — PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced today the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’s current investors include Novartis …